Safimaltib was recently developed as a specific MALT1 paracaspase inhibitor (40), and it is currently under early clinical investigation in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia (ClinicalTrials.gov NCT03900598). This evidence concerns the gene MALT1 and non-Hodgkin lymphoma.